CN111757877B - 甲基内酰胺环化合物及其药物用途 - Google Patents

甲基内酰胺环化合物及其药物用途 Download PDF

Info

Publication number
CN111757877B
CN111757877B CN201980016238.4A CN201980016238A CN111757877B CN 111757877 B CN111757877 B CN 111757877B CN 201980016238 A CN201980016238 A CN 201980016238A CN 111757877 B CN111757877 B CN 111757877B
Authority
CN
China
Prior art keywords
compound
acid
formula
reaction mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980016238.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111757877A (zh
Inventor
三浦智也
玉谷义宪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CN111757877A publication Critical patent/CN111757877A/zh
Application granted granted Critical
Publication of CN111757877B publication Critical patent/CN111757877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980016238.4A 2018-03-01 2019-02-28 甲基内酰胺环化合物及其药物用途 Active CN111757877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
JP2018-036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
CN111757877A CN111757877A (zh) 2020-10-09
CN111757877B true CN111757877B (zh) 2023-10-27

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980016238.4A Active CN111757877B (zh) 2018-03-01 2019-02-28 甲基内酰胺环化合物及其药物用途

Country Status (21)

Country Link
US (3) US11014910B2 (https=)
EP (1) EP3760624A4 (https=)
JP (3) JP7206132B2 (https=)
KR (1) KR102795351B1 (https=)
CN (1) CN111757877B (https=)
AR (1) AR114418A1 (https=)
AU (1) AU2019227770B2 (https=)
BR (1) BR112020016788A2 (https=)
CA (1) CA3087859A1 (https=)
CL (1) CL2020002199A1 (https=)
IL (1) IL276311B2 (https=)
MA (1) MA52427A (https=)
MX (1) MX2020009070A (https=)
MY (1) MY205197A (https=)
PE (1) PE20210123A1 (https=)
PH (1) PH12020551340A1 (https=)
SA (1) SA520420037B1 (https=)
SG (1) SG11202007120UA (https=)
TW (1) TWI805699B (https=)
WO (1) WO2019168096A1 (https=)
ZA (1) ZA202004600B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
US20230119894A1 (en) * 2019-09-04 2023-04-20 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3175131A1 (en) 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
CN103917535A (zh) * 2011-08-31 2014-07-09 日本烟草产业株式会社 吡唑化合物和其药物用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP2026798A1 (en) * 2006-04-27 2009-02-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP5583003B2 (ja) * 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
CN109071454B (zh) * 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
CN103917535A (zh) * 2011-08-31 2014-07-09 日本烟草产业株式会社 吡唑化合物和其药物用途

Also Published As

Publication number Publication date
CL2020002199A1 (es) 2020-12-18
JP2023026566A (ja) 2023-02-24
MA52427A (fr) 2021-01-06
SA520420037B1 (ar) 2024-07-28
TWI805699B (zh) 2023-06-21
CN111757877A (zh) 2020-10-09
EP3760624A4 (en) 2021-11-03
PH12020551340A1 (en) 2021-05-31
US20190352284A1 (en) 2019-11-21
WO2019168096A1 (ja) 2019-09-06
MY205197A (en) 2024-10-07
US11014910B2 (en) 2021-05-25
CA3087859A1 (en) 2019-09-06
AU2019227770A1 (en) 2020-07-09
RU2020131756A (ru) 2022-03-28
TW202000660A (zh) 2020-01-01
BR112020016788A2 (pt) 2021-01-12
AR114418A1 (es) 2020-09-02
ZA202004600B (en) 2022-03-30
JP2019151627A (ja) 2019-09-12
IL276311A (en) 2020-09-30
JP2025026615A (ja) 2025-02-21
MX2020009070A (es) 2020-10-08
KR102795351B1 (ko) 2025-04-16
IL276311B2 (en) 2023-10-01
IL276311B1 (en) 2023-06-01
US20240174646A1 (en) 2024-05-30
EP3760624A1 (en) 2021-01-06
JP7206132B2 (ja) 2023-01-17
SG11202007120UA (en) 2020-08-28
KR20200128033A (ko) 2020-11-11
PE20210123A1 (es) 2021-01-19
US20220064148A1 (en) 2022-03-03
AU2019227770B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CN111757877B (zh) 甲基内酰胺环化合物及其药物用途
CN111902408B (zh) 杂芳基取代的吡唑化合物及其药物用途
CN114585387B (zh) 利用联用药物的糖尿病的治疗或预防方法
JP2025138791A (ja) 慢性腎臓病の治療又は予防方法
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
HK40044833A (en) Methyllactam ring compound and medicinal use thereof
HK40068410A (en) Chronic kidney disease treatment or prevention method
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant